-
Mashup Score: 24
The application of artificial intelligence (AI) in oncology is still in its infancy, even though the advantages of AI could extend to numerous areas, including clinical trial matching, therapeutic decision-making, and patient outcomes.
Source: ASCO Daily NewsCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @anita_turk: Excited to learn how to use AI and computer learning to cancer cancer care! #GI23 https://t.co/Ar36wYkok6
-
RT @ASCO: Happening now! #GI23 keynote with @mattlungrenMD: AI in Oncology More in #ASCODailyNews ➡️ https://t.co/4igyydNJSN #HealthAI #On…
-
RT @anita_turk: Excited to learn how to use AI and computer learning to cancer cancer care! #GI23 https://t.co/Ar36wYkok6
-
Happening now! #GI23 keynote with @mattlungrenMD: AI in Oncology More in #ASCODailyNews ➡️ https://t.co/4igyydNJSN #HealthAI #OncTwitter https://t.co/H7Ki8h5Mnw
-
-
Mashup Score: 4
The application of artificial intelligence (AI) in oncology is still in its infancy, even though the advantages of AI could extend to numerous areas, including clinical trial matching, therapeutic decision-making, and patient outcomes.
Source: ASCO Daily NewsCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @ColonCancerDoc: Looking so forward to an exciting @ASCO #GI23 Keynote with @mattlungrenMD https://t.co/T7RiTCWyhs
-
RT @ColonCancerDoc: Looking so forward to an exciting @ASCO #GI23 Keynote with @mattlungrenMD https://t.co/T7RiTCWyhs
-
-
Mashup Score: 1
Patients with cholangiocarcinoma harboring FGFR alterations (FGFRalt) who were treated with open-label erdafitinib had an objective response rate by independent review of 60%, with a median time to onset of response of 1.5 months (Abstract 610).
Source: ASCO Daily NewsCategories: Hem/Oncs, Latest HeadlinesTweet-
🚨🚨#Erdafitinib 🎯in patients with #cholangiocarcinoma and #FGFR alterations @ASCO #GI23 ➡️ ORR 60% ➡️ DCR 100% ➡️ Median PFS 8.4 months 🙏🙏 Patients, caregivers, co-investigators, advocates https://t.co/Ahlm54Lxoi
-
-
Mashup Score: 16
First-line treatment with zolbetuximab plus mFOLFOX6 significantly improved progression-free and overall survival in patients with Claudin 18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or GEJ adenocarcinoma (LBA292).
Source: ASCO Daily NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Practice-changing research from #GI23: Zolbetuximab + mFOLFOX6 meets primary endpoint in SPOTLIGHT trial, improves PFS, OS in pts w/ CLDN18.2+, HER2-negative, locally advanced unresectable or metastatic gastric or GEJ cancer: https://t.co/5N2pBLFKFF #ASCODailyNews #gicsm #esocsm
-
-
Mashup Score: 3
Final results from the INTEGRATE-IIa trial in patients with advanced GEJ showed improved overall survival in participants treated with regorafenib compared with the placebo. The 12-month survival rate was 19% with regorafenib and 6% for placebo (LBA294).
Source: ASCO Daily NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Final INTEGRATE-IIa results from #GI23: Regorafenib improves survival in refractory advanced GEJ. 12-month survival rate was 19% with regorafenib and 6% for placebo. #ASCODailyNews has more: https://t.co/jBWCcTdq8p #gicsm
-
-
Mashup Score: 2Transitioning to Total Neoadjuvant Therapy: Evolution of Therapeutic Management for Patients With Rectal Cancer - 2 year(s) ago
The shift toward total neoadjuvant therapy for locally advanced rectal cancer has improved outcomes, but opportunities remain to further improve disease control and augment availability of nonoperative management options.
Source: ASCO Daily NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Oncologists from @DukeMedSchool discuss how the shift toward TNT for LARC treatment has improved outcomes, but opportunities remain to further improve disease control & augment availability of NOM options: https://t.co/uL4749R7UM #GI23 #ASCODailyNews @AcklinScarlett
-
-
Mashup Score: 4Study Finds Relationship Between Food Insecurity and Gastrointestinal Cancer Mortality - 2 year(s) ago
A study of food insecurity measures and deaths from GI cancers in the United States found that areas with high levels of food insecurity had greater rates of GI cancer mortality (Abstract 788). Clinicians should ask patients if they are having difficulty gaining access to adequate nutrition during treatment.
Source: ASCO Daily NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
A new study from #GI23 finds that areas in the U.S. with high levels of food insecurity also have greater rates of GI cancer mortality, reinforcing the importance of adequate #nutrition during treatment. #ASCODailyNews has more: https://t.co/dtmJvQOzPr #gicsm
-
-
Mashup Score: 4Real-World Analysis Shows Utility of ctDNA Kinetics in Patients With Advanced Colorectal Cancer - 2 year(s) ago
An analysis of real-world circulating tumor DNA (ctDNA) kinetics data using a clinically validated algorithm found that patients with advanced colorectal cancer categorized as molecular responders had longer time on treatment and better overall survival (OS; Abstract 246).
Source: ASCO Daily NewsCategories: Hem/Oncs, Latest HeadlinesTweet-
🗞️Just Published. #ASCODailyNews 🔦 highlighting our work on: #ctDNA🩸🧬 kinetics 📈📉. t1/2 few hours/days. ➡️utility in this being a powerful tool that could be utilized in adaptive #clinicaltrials & beyond. @OncoAlert more to come @ASCO #GI23 📰Link https://t.co/64Bf8Nd6w1 https://t.co/uhCMvGA69t
-
-
Mashup Score: 1
The application of artificial intelligence (AI) in oncology is still in its infancy, even though the advantages of AI could extend to numerous areas, including clinical trial matching, therapeutic decision-making, and patient outcomes.
Source: ASCO Daily NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In his upcoming #GI23 keynote lecture, @mattlungrenMD will present the latest developments, current challenges, & auspicious future of #AI in oncology and health care. #ASCODailyNews has more: https://t.co/8e7GAVyREV #healthdata
-
-
Mashup Score: 3Gastrointestinal Cancers Symposium | ASCO Daily News - 2 year(s) ago
The latest scientific coverage and expert insights from the ASCO Gastrointestinal Cancers Symposium, all in one place.
Source: ASCO Daily NewsCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Research from #GI23 is now available! #ASCODailyNews is covering just-released abstracts from the upcoming Symposium, read all articles now: https://t.co/jFzI1z9IVe #gicsm #OncTwitter
-
RT @ASCO: Happening now! #GI23 keynote with @mattlungrenMD: AI in Oncology More in #ASCODailyNews ➡️ https://t.co/4igyydNJSN #HealthAI #On…